Sponsored by
xUtility is a set of tools and a regulatory grade dataset of de-identified cancer patient data. This can easily be used to create a synthetic control group for a clinical trial. This means we do not really need placebos any more! By being able to match patient characteristics along with the biomarkers, a valid control group can be created. We could also go back and reanalyze phase 2 trials with matched synthetic controls to better see how they are doing. A major problem in the past was phase 2 trials results appeared great when compared to the median survival of all patients, then when they get into a phase 3 trial they fail. The main cause is those patients in the phase 2 trial were not typical and would have lived longer even without the experimental treatment. Now we can go back and create matched controls to really tell how the phase 2 trial went. This could avoid phase 3 trials that are doomed to fail - saving lives! This is a major advance.
Disclaimer: I am proud to say that I am a paid consultant for xCures and own stock in xCures!